Clinical Trials Logo

Filter by:
NCT ID: NCT05806697 Not yet recruiting - Alzheimer Disease Clinical Trials

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study

INSIGHT-2
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the natural history of preclinical Alzheimer's disease (AD). The primary endpoint is the conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir positron emission tomography (PET) imaging. The size of the cohort is estimated to around 240 participants (61 A+ subjects) among the 318 participants included in the main cohort (88 A+ subjects). The follow-up in the INSIGHT-2 cohort will be lightened compared to that of the main cohort with an annual frequency of visits rather than a six-monthly one.

NCT ID: NCT05813483 Not yet recruiting - Photo-damaging Clinical Trials

A Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser Treatment

Start date: April 17, 2023
Phase: N/A
Study type: Interventional

A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and satisfaction of the Skinceuticals skin care product (CE) for skin repair following fraxel laser treatment and explore the medical value of fraxel laser therapy combined with Skinceuticals skin care product

NCT ID: NCT05821621 Not yet recruiting - Clinical trials for Food Allergy in Children

Efficacy and Safety of Cashew Nut Oral Immunotherapy in Children

CAJESITO2
Start date: April 17, 2023
Phase:
Study type: Observational

Allergy to nuts (cashew, pistachio, walnut, exotic nuts) is a frequent allergy in children, with a prevalence of up to 4.9% of the population and a low resolution rate (9%). Among the nut allergies, cashew nut allergy is one of the most frequent in Northern Europe: in France 41% of children allergic to nuts are sensitized to cashew nuts. Moreover, cashew nut allergy is associated with severe reactions that can be lethal in both adults and children. These reactions may even be more severe than those observed with peanuts, with more frequent respiratory and cardiovascular impairment. We note reactions for even limited contacts (cutaneous or mucous) and low reactogenic thresholds. However, the only recommendation for management at present is avoidance. The stakes of oral immunotherapy protocols cashew would be similar to those for peanut immunotherapy: to limit reactions in case of accidental intake, increase the reactogenic threshold and thus improve the quality of life of allergic patients. To date, only one study has focused on the efficacy and tolerance of cashew immunotherapy : the prospective NUT CRACKER study conducted on 50 children aged 4 years or older with cashew nut allergy between 2016 and 2019, reports a good efficacy of immunotherapy on increasing threshold for cashew nut but also for pistachio and walnut, when there was a cross-over allergy. While the tolerance was similar to other immunotherapy protocols for the other foods. The objectives of part 2 of the CAJESITO study are (i) to evaluate the tolerance of oral cashew nut immunotherapy, by describing the frequency and severity of allergic reactions during oral cashew immunotherapy and (ii) to identify risk factors for severe risk factors for severe allergic reactions during oral cashew immunotherapy.

NCT ID: NCT05829616 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.

NCT ID: NCT05833152 Not yet recruiting - Clinical trials for Total Knee Arthroplasty

Correlation Between Preoperative Knee Extension Lag and Functional Outcome After Total Knee Arthroplasty

Start date: April 17, 2023
Phase:
Study type: Observational

To explore the relationship between different knee extension hysteresis angles and functional outcome of knee joint after total knee replacement

NCT ID: NCT06233864 Not yet recruiting - Pancreatic Cancer Clinical Trials

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This is a phase 2 clinical study,to explore the efficacy and safety of Disitamab Vedotin in patients with locally advanced or metastatic pancreatic cancer expressing HER2.

NCT ID: NCT06341829 Not yet recruiting - Parkinson Disease Clinical Trials

Visuospatial and Affective Abilities in Parkinson Disease

Start date: April 17, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to investigate whether prismatic adaptation (AP), a non-invasive neuromodulation technique, that involves the use of lenses that deviate the visual field, can modulate alexithyima and performance in visuospatial tasks in patients with Parkinson disease. Furthermore, brain activity during the prismatic adaptation and post-adaptation phases will be recorded using functional near-infrared spectroscopy (fNIRS) and high-density electroencephalography (HD-EEG).

NCT ID: NCT06387810 Not yet recruiting - Clinical trials for Borderline Resectable Pancreatic Cancer

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

undetermined
Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.

NCT ID: NCT04294186 Not yet recruiting - Diaper Dermatitis Clinical Trials

Evaluation of Factors Affecting Diaper Dermatitis

Start date: April 18, 2020
Phase:
Study type: Observational

Diaper dermatitis is one of the most common skin problems in infants and children.It is a skin disorder in the perineal , perianal and surrounding area .It frequently occurs also in areas immediately adjacent to the diaper area . Diaper dermatitis is caused by lack of fresh air,dampness and irritation.With prevelance from 7-35 % in newborns.This skin disorder typically develops between nine and twelve months of age .

NCT ID: NCT04853706 Not yet recruiting - Delirium Clinical Trials

Validation of the 3D-CAM Turkish Version

Start date: April 18, 2021
Phase: N/A
Study type: Interventional

3D CAM into Turkish validity and reliability on postoperative delirium will be test as a prospective diagnostic study. After approval by Dr. Edward R. Marcantonio, (15) will translation and back-translation. The original 3D-CAM will translate into Turkish by two medical doctor .The two translational versions will be discussed and merged into a final version. Back translation will performed in regardless of any information from its original version by another two medical doctor. Both the translated and back translated versions will sent to Dr. Marcantonio for approval. Eligibility and the documentation of consent will be confirmed at the preoperative visit. During this visit, patients will provide demographic and historical medical information, including information regarding medication usage. The Mini-Mental State Exam (MMSE) will be performed. Delirium assessment Delirium assessment with the 3D-CAM Before the study period, all researchers will participate online training program on 3D CAM. Delirium will be evaluated using the 3D CAM every each morning and evening (18:00-20:00) for postoperative 3 days. Delirium assessment with the DSM-5 The psychiatrist investigator who was blinded to the 3D-CAM assessment results, will evaluate the patients according to the criteria of DSM-5 within 3 min after the 3D-CAM assessment.